NATURAL PRODUCT RESEARCH AND DEVELOPMENT ›› 2023, Vol. 35 ›› Issue (12): 2049-2060. doi: 10.16333/j.1001-6880.2023.12.004

Previous Articles     Next Articles

In silico evaluation of pancreatic lipase inhibitory peptide in camel blood protein

YI Li1,2*,SUN Ru-xin1,HE Jing1,2,MING Liang1,2,ZHANG Xiu-rong3,Jirimutu1,2   

  1. 1Key Laboratory of Dairy Biotechnology and Bioengineering,Ministry of Education,College of Food Science and Engineering,Inner Mongolia Agriculture University,Hohhot 010018,China;2 Inner Mongolia China-Kazakhstan Camel Research Institute,Alxa 737300,China;3Alxa Right Banner Agricultural Technology Promotion Center,Alxa 750306,China
  • Online:2023-12-28 Published:2023-12-27

Abstract:

In this study,camel blood proteins were enzymatically digested using neutral protease,and the enzymatic process,pancreatic lipase (PL,PDB code:1ETH) inhibitory activity,molecular characteristics of the peptides,and molecular binding patterns were investigated with the aim of PL inhibitory peptides.The optimal processing conditions were 5% neutral protease,pH was 7.0,enzymolysis temperature was 55 ℃,and enzymolysis time was 3 h.Under optimized conditions,the PL inhibition rate reached 42.13%.A total of 533 peptides were identified using LC-MS/MS,of which eight peptides had a PeptideRanker score greater than 0.8.Among them,ALERMFLGF,GQPAVPVRF,and WDPSKVPPR exhibited significant binding with pancreatic lipase.Molecular dynamic simulation by AMBER 19 showed that all of them could interact with the residues in the active pocket residues of PL,primarily through electrostatic interactions,hydrogen bonding and hydrophobic interactions,thereby inhibiting its activity.Among them,CGPAVPVRF stands out the most potent PL inhibitor peptide,exhibiting the highest binding energy and possessing a greater number of binding sites.The study not only provides a reference for the development of novel PL inhibitor peptides,but also offers a new avenue for the high-value utilization of camel blood proteins.

Key words: camel blood protein, pancreatic lipase, bioactive peptide, molecular dynamic simulation

CLC Number: